Adreview (123i)

Adreview (123i) is a diagnostic radiopharmaceutical containing Iodine (123i) Iobenguane, used for imaging certain types of tumors. This intravenous medication is manufactured by GE Healthcare SAS and is designed for precise diagnostic purposes.

Adreview (123i) is primarily used in medical imaging to help visualize and assess the function of certain tissues and organs. It is often employed in the diagnosis and monitoring of specific types of tumors. The medication works by binding to specific cells, allowing healthcare professionals to identify areas of interest through imaging techniques.

Adreview (123i) is designed to provide clear images of targeted areas, aiding in the diagnosis and monitoring of conditions. Common effects may include temporary discomfort at the injection site, but these are generally mild and short-lived. The medication is intended for use under professional supervision to ensure accurate results.

Adreview (123i) should be handled with care, following all safety protocols for radiopharmaceuticals. It is important to inform healthcare providers of any allergies or medical conditions before administration. Proper disposal and handling procedures must be followed to minimize exposure and ensure safety.

Adreview (123i) may interact with certain medications or substances, so it is important to discuss all current treatments with a healthcare provider. Specific interactions with other radiopharmaceuticals or contrast agents should be considered to avoid potential complications.